Infliximab
EAS |
Nº pacientes |
Respuesta terapéutica n (%) |
Efectos adversos n (%) |
Mortalidad |
|---|---|---|---|---|
BEHCET |
133 |
89,47 |
30,82 |
1 |
CHURG-STRAUSS |
4 |
50 |
0 |
0 |
CRYOGLOBULINEMIA |
4 |
25 |
25 |
2 |
DERMATOMYOSITIS |
9 |
77,77 |
55,55 |
1 |
SYSTEMIC SCLEROSIS |
4 |
75 |
50 |
1 |
RPGN-ANCA |
1 |
100 |
0 |
0 |
HORTON |
37 |
56,75 |
54,05 |
0 |
SLE |
9 |
100 |
33,33 |
0 |
PAM |
13 |
76,92 |
23,07 |
1 |
PAN |
2 |
100 |
0 |
0 |
POLICONDRITIS |
8 |
87,5 |
25 |
1 |
RHEUMATIC POLIMYALGIA |
20 |
30 |
Not specified |
0 |
POLIMYOSITIS |
8 |
87,5 |
50 |
1 |
SARCOIDOSIS |
154 |
99,35 |
57,79 |
3 |
SJOGREN |
65 |
30,76 |
18,46 |
0 |
ADULT-ONSET STILL |
49 |
87,75 |
26,53 |
0 |
WEGENER |
42 |
78,57 |
21,42 |
0 |
Total |
562 |
79,00 |
36,30 |
11 (1,95%) |